MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings data on Monday. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.04, Bloomberg Earnings reports. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. MyoKardia had a negative net margin of 39.44% and a negative return on equity of 15.27%. The business’s revenue was up 60.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.37) earnings per share.

Shares of MyoKardia (NASDAQ:MYOK) opened at 17.15 on Monday. MyoKardia has a 52 week low of $10.55 and a 52 week high of $22.83. The stock’s 50 day moving average price is $14.02 and its 200-day moving average price is $13.13. The stock’s market cap is $539.45 million.

Several analysts recently weighed in on MYOK shares. BMO Capital Markets restated an “outperform” rating and issued a $32.00 price objective on shares of MyoKardia in a report on Wednesday, May 10th. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. TheStreet lowered MyoKardia from a “c-” rating to a “d+” rating in a research note on Friday, May 19th. Finally, BidaskClub upgraded MyoKardia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $24.75.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/myokardia-inc-nasdaqmyok-posts-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

In other MyoKardia news, CEO Anastasios Gianakakos sold 4,300 shares of the stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $16.62, for a total value of $71,466.00. Following the sale, the chief executive officer now owns 512,463 shares of the company’s stock, valued at approximately $8,517,135.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 46.10% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in MyoKardia by 12.5% in the first quarter. Wellington Management Group LLP now owns 3,154,734 shares of the biotechnology company’s stock worth $41,485,000 after buying an additional 349,768 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in MyoKardia during the first quarter worth about $1,577,000. Marshall Wace North America L.P. bought a new stake in MyoKardia during the first quarter worth about $1,577,000. Point72 Asset Management L.P. bought a new stake in MyoKardia during the first quarter worth about $1,546,000. Finally, TFS Capital LLC bought a new stake in MyoKardia during the first quarter worth about $934,000. 47.74% of the stock is currently owned by institutional investors.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Earnings History for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.